Alamar Biosciences, Inc.

ALMR Nasdaq SEC CIK 2104204
Follow Alamar Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $33.5M +68.5% vs same quarter last year
Net income −$13.3M −66.8% vs same quarter last year
EPS, diluted −$0.19 +72.5% vs same quarter last year
Operating cash flow −$14.7M −4.2% vs same quarter last year
Revenue by quarter
$13.1M
$16.2M
$19.9M
$26M
$29.4M
$33.5M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing